Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been shown to be a promising and effective treatment for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, there is a lack of evidence-based data demonstrating the impact of ICIs on HBV DNA level in HBV-HCC patients undergoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kunyuan, Xia, Ying, Zhu, Yun, Yu, Wenxuan, Guo, Yabing, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578995/
http://dx.doi.org/10.1136/jitc-2021-003195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578995/
http://dx.doi.org/10.1136/jitc-2021-003195

Ejemplares similares